Related Experiment Video

Updated: Jun 1, 2026

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Interleukin-2 and interferon alpha 2 combination

P Pronzato1, A Vigani, F Vaira

  • 1OSPED S ANDREA,DEPT UROL,I-19100 LA SPEZIA,ITALY. OSPED S ANDREA,DEPT RADIOTHERAPY,I-19100 LA SPEZIA,ITALY.

Oncology Reports
|May 20, 2011
PubMed

Insights

This study found that subcutaneous recombinant interleukin-2 and interferon alpha 2b showed acceptable toxicity but no objective response in advanced renal cell carcinoma patients. Median survival was 16 months in this pretreated group.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Advanced renal cell carcinoma (RCC) has limited treatment options.
  • Interferon therapy is a known treatment for RCC.
  • Recombinant interleukin-2 (IL-2) is being explored for its anti-cancer effects.

Purpose of the Study:

  • To evaluate the activity and toxicity of subcutaneous recombinant IL-2 combined with interferon alpha 2b.
  • To assess the outcomes in patients with advanced RCC who had poor prognostic factors and prior interferon treatment.

Main Methods:

  • A series of 14 patients with advanced RCC were treated with subcutaneous recombinant IL-2 and interferon alpha 2b.
  • Patients had pre-existing poor prognostic factors and had received prior interferon therapy.

Main Results:

  • No objective tumor response was observed in any of the patients.
  • The median survival time for the group was 16 months, with a range of 3 to 19 months.
  • The toxicity associated with the treatment regimen was deemed acceptable.

Conclusions:

  • Subcutaneous recombinant IL-2 and interferon alpha 2b combination therapy did not yield objective responses in pretreated advanced RCC patients.
  • The treatment demonstrated acceptable toxicity despite poor prognostic factors.
  • Further research may be needed to identify effective immunotherapy combinations for advanced RCC.

More Related Videos

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD22608:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...